There is no longer a need for verification of the importance of gut microbiota in human health, the major role of this organ is now well established. It appears particularly active in inflammatory bowel disease (IBD).
In 2008, Faecalibacterium prausnitzii (F. prausnitzii) was the first commensal anti-inflammatory bacterium identified on the basis of human clinical data (comparison of microbiota between IBD patients in remission and in relapse). Since this discovery, many studies have examined the correlations between F. prausnitzii and human intestinal dysbiotic diseases. This abundant and ubiquitous bacteria of our gut microbiota could, in the near future, play a major role in the new preventive and therapeutic strategies for gastrointestinal diseases. Thus, F. prausnitzii has great potential as a next generation probiotic for IBD patients.

Author
Pr. Philippe LANGELLA
Author
Pr. Philippe LANGELLA
Category
Immunology
Publication type
Proceedings
Year
2018
Download the publication